Market Access Views & Analysis

Views & Analysis

Market Access

NICE’s health inequalities modular update: A positive step, ...

The start of a new year saw the launch of a consultation on NICE’s eagerly anticipated health inequalities modular update to the manual for health technology evaluation.1

Market Access

NICE contribution to the cost per QALY threshold debate?

Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency and highlights the opportunity for stakeholders to build their c

Market Access

skyscrapers with overlay of financial graphs

The outlook for healthtech and life sciences in 2025

2024 was pivotal for UK Life Sciences’ venture funding landscape.

Market Access

DNA Molecular Genetic Science Biotechnology

Overcoming barriers for global CGT adoption

Cell and gene therapies (CGT) have emerged as the next big thing in medicine, holding the power to deliver cures where none previously existed.

Market Access

Looking ahead in 2025 and MHRA reliance

International reliance is a mechanism whereby certain medical devices could access the UK market more quickly if they have already been approved by a comparable regulator, rather than under

Market Access